Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697148 · ClinicalTrials.gov registry record · NA
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
A NA study of Prostate Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 852
- Enrollment target
- 20
- Study locations
NCT03697148: Active NA study of Prostate Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.
NCT03697148 is a NA study of Prostate Carcinoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 852 participants, below the 1,487-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03697148, a NA study of Prostate Carcinoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 852 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Primary Outcome
Will estimate the diagnostic performance as quantified by the area under the ROC curve.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Multiparametric Magnetic Resonance Imaging
Study Locations (20)
Hawaii
- Queen's Medical Center - Honolulu
- Straub Clinic and Hospital - Honolulu
- Pali Momi Medical Center - ‘Aiea
- Straub Pearlridge Clinic - ‘Aiea
Michigan
- Henry Ford Hospital - Detroit
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital - Grand Rapids
- Henry Ford West Bloomfield Hospital - West Bloomfield
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Florida
- University of Florida Health Science Center - Jacksonville - Jacksonville
- Mayo Clinic in Florida - Jacksonville
Kansas
- University of Kansas Cancer Center - Kansas City
- University of Kansas Hospital-Indian Creek Campus - Overland Park
Louisiana
- East Jefferson General Hospital - Metairie
- LSU Healthcare Network / Metairie Multi-Specialty Clinic - Metairie
Connecticut
- Yale University - New Haven
Illinois
- Midwestern Regional Medical Center - Zion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What the registry record for NCT03697148 still lists
NCT03697148 is an interventional study that assigns participants to a tested intervention. The registered 852 participants enrollment target is mid-sized for trials with a published cap, below the 1,487-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Multiparametric Magnetic Resonance Imaging is the first listed.
NCT03697148 names 20 study sites across 11 states, led by Hawaii, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT03697148 about?
NCT03697148 is a clinical study titled "Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer". This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
What is the current status of trial NCT03697148?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 852 participants. The study started on 2019-02-11. Estimated completion is 2026-08-31.
What conditions does trial NCT03697148 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT03697148?
The interventions under investigation include: Multiparametric Magnetic Resonance Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03697148?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03697148 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03697148's enrollment target sits among peer trials
852 4th of 59 higher than 56 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
RECRUITING · NA
-
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
RECRUITING · NA
-
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
RECRUITING · NA
-
Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI